Skip to main content
. 2017 Jul 24;28(10):2420–2428. doi: 10.1093/annonc/mdx397

Figure 1.

Figure 1.

Time to recurrence (TTR) and overall survival (OS) analysis. (A) TTR and (B) OS curves for patients with tumors with <1% of ER expression (ER < 1%), patients with tumors with ≥1% but <10% of ER expression (1% ≤ ER < 10%), and patients with tumors with ≥10% of ER expression (ER ≥ 10%). (C) TTR and (D) OS curves for patients with tumors with <10% of ER expression (ER < 10%) and patients with tumors with ≥10% of ER expression (ER ≥ 10%).